Fujirebio Group aims to develop and manufacture diagnostic products with new clinical value to the global market. Since our foundation in 1950 and the start of our diagnostic business in 1966, our focus has constantly been on innovation, stable supply and quality.
Today, as part of the H.U. Group, we prove the value of our new markers on our Lumipulse® and ESPLINE® platforms. Through various business models and broad partnerships, we aim to deliver our markers to the global community. Our R&D and manufacturing capabilities are located in Japan, Europe and US, working closely with our partners.
We value partnerships. Being considered as a trusted partner is key to our strategy. We are committed to fulfilling our responsibility in the global society through our business.
Goki Ishikawa, President & CEO of Fujirebio Holdings, Inc.